Advisory · Oncology
The most actively transacted therapeutic area in biopharma.
Ambrosia provides senior-led advisory for oncology licensing, M&A, and strategic partnerships — backed by a proprietary database of 875 verified oncology transactions.
Deal Landscape
What oncology transactions actually look like.
Verified Transactions
875
Median Upfront
$95M
Key Structure Insight
ADC and bispecific deals command 30-40% premiums over small molecule
Selected Work
Oncology·Phase 2 ADC asset — ex-US territorial out-licensing to a top-10 pharma partner
Oncology·Bispecific oncology platform — cross-border M&A execution through close
Related Insights
Research relevant to oncology.
Stay Informed
Get new deal intelligence and transaction insights as we publish them.
No spam. Unsubscribe anytime.
Discuss your oncology transaction.
We’ll meet you at peer level — anywhere in the world.